FOLH1 and non-small cell lung carcinoma: Only a few papers describe the use of PDX models in the field of TRT, focusing on PSMA-positive and PSMA-negative PCa [124], non-small cell lung cancer (NSCLC) [125] and acute lymphoblastic and myeloid leukaemia [126].